Fast movers • Alerts • Momentum
10% OFF with SAVE10
Charts • Watchlists • Multi-broker tools
Built for active traders
Biotech catalyst, news and analysis PDUFA tracker
Biotech catalyst, news and analysis PDUFA tracker
Today’s biotech tape is not built around one single mega-cap headline. It is a classic catalyst radar session: one small oncology name with a fresh Phase 2a survival signal, one late-stage inflammatory disease story with a major Phase 3/NDA setup but financing pressure, one infectious-disease micro-cap tied to babesiosis development, and one diabetes medtech name moving from clearance into real-world use.
Abivax has moved from a speculative French biotech story to one of the most closely watched late-stage ulcerative colitis names in global healthcare. The June 29 ABTECT Maintenance Part 2 update did not simply add another dataset. It directly addressed the safety debate that had pressured the stock after the June 1 maintenance readout and pushed investors to reassess the risk/reward profile ahead of the planned U.S. NDA submission in Q4 2026.
Deep Dive · Defense Autonomy · $VWAV VisionWave Holdings (Nasdaq: $VWAV): Meteor Aerospace Deal Turns the Pre-Market Spike Into a Real Defense-Autonomy Test VisionWave announced a definitive binding agreement to acquire a 51% controlling interest in Meteor Aerospace, an Israeli…
The market did not get a final ruling today. What it got is the start of a federal process that could decide whether the cannabis trade remains a narrow medical-only tax story or becomes a broader sector repricing catalyst.
A deeper, U.S.-focused Merlintrader editorial on how to read sell-side price targets in small and mid-cap biotech, why 12-month targets often fail as forecasts, and why binary events such as PDUFA dates, Phase 3 readouts and FDA advisory committees can turn the “average target” into a misleading comfort number.
The public space sector just received a concentrated set of catalysts: Rocket Lab is trying to buy an operating satellite communications network, AST SpaceMobile has placed its next BlueBird batch on the launch calendar, and NASA has selected Rocket Lab for dedicated Sun/Earth science missions. Together, these updates show how the investable space trade is moving beyond launch hype and into infrastructure, networks, services, and execution.
The biotech calendar is entering a dense FDA-driven window, with three Nasdaq-listed names standing out for very different reasons: a renal-disease PDUFA decision watch, a rare-disease cell therapy advisory committee, and an oncology BLA resubmission that has put accelerated approval back in focus.
Space Economy · $ASTS · $RKLB · $SPCE · $FJET Space Economy 2026: $ASTS vs $RKLB vs $SPCE vs $FJET — Four Business Models Compared A focused comparison of four publicly traded US space-economy names: satellite-to-phone connectivity ($ASTS), launch and…
A sector-by-sector operational screen of the June 2026 Russell reconstitution, focused on stocks that deserve attention after the index event because chart structure, post-rebalance volume, fundamentals, catalysts and analyst target references overlap.
The June space trade is no longer being priced stock by stock. Planet Labs, Intuitive Machines, Satellogic, AST SpaceMobile and Rocket Lab are being traded as one high-beta space basket — and the unwind has exposed the same pressure points across the sector: SpaceX gravity, ETF outflows, valuation resets, execution risk, launch cadence, defense-contract timing and profit-taking after a crowded rally.
RUSSELL 2026 PRELIMINARY LIST 87 HEALTH CARE ADDITIONS BIOTECH FOCUS Russell 2026 Biotech Watchlist: $UNCY, $GALT, $SPRB, $OVID and the Small-Cap Health Care Additions to Watch The June 2026 Russell reconstitution becomes effective after the U.S. market close on June…
ARQT, LNTH and UNCY face FDA target action dates on June 29, while VRDN follows on June 30. The setup spans pediatric dermatology, nuclear medicine imaging, dialysis-related nephrology and thyroid eye disease — four very different regulatory events with very different trading profiles.
Report date: June 25, 2026
Financial data: latest Q1 2026 updates where available
Three healthcare small caps enter the morning radar for different reasons: Pulsenmore is pushing FDA-authorized home ultrasound into U.S. virtual maternity care, IceCure is building the clinical-validation story around ProSense cryoablation, and Silence Therapeutics is moving closer to a Phase 2 SANRECO readout for divesiran in polycythemia vera.
SpaceX’s massive financing push, Rocket Lab’s record-setting rapid-response U.S. Space Force mission, and the SB-AMTI sensing architecture point toward a bigger market theme: the next phase of the space trade may be less about launch spectacle and more about military infrastructure, orbital resilience, sensor networks, and defense procurement.
The FDA approval of TRYNGOLZA in adults with severe hypertriglyceridemia turns olezarsen from a rare-disease FCS launch into a broader cardiometabolic commercial story. The key issue now is not simply whether the drug works, but how quickly Ionis can convert a stronger label, a larger addressable population and pancreatitis-risk messaging into real prescribing momentum.
Phase 3 clinical data, analyst coverage and an international licensing deal: three real, verified catalysts across DFTX, ABSI and NVCT.
From overlooked micro-cap to AI data center power story: MCFC fuel-cell technology, the gigawatt-scale commercial pivot, and the Russell 2000 watch into Friday, June 26, 2026.
A verified deep dive on Annamycin, the MIRACLE Phase 2b/3 trial, the latest cardiac-safety package, the company’s fragile cash position, and the binary scenarios surrounding the first 45-subject interim unblinding expected by June 30, 2026.
NASDAQ: SPCX Market Analysis IPO / Space / AI SpaceX (Nasdaq: $SPCX): The Party Lasted Four Days. Then Came the Bill. The largest IPO in market history pushed SpaceX into the center of the global tape: $135 pricing, roughly $75…
Three biotech updates hit the tape today with very different market meanings: Taysha delivered the strongest clinical/regulatory signal, Entera Bio reduced Phase 3 design uncertainty around EB613, and Scholar Rock added a near-term neuromuscular conference watch around SMA and FSHD